Pharma Pivot or Personal Vendetta? The Accord Healthcare Redundancy Dispute

In the high-stakes world of pharmaceutical corporate strategy, the line between a “strategic pivot” and “unfair dismissal” is often thin. A current case before the Workplace Relations Commission (WRC) highlights this tension, as a former senior manager at Accord Healthcare Ireland Ltd alleges she was misled about job security just days before her own role was eliminated.

The dispute centers on a fundamental conflict: was the redundancy a necessary result of a company-wide shift in business model, or was it a targeted move against an employee who pushed for better compensation?

The Claim: Reassurance Followed by Redundancy

Tracey Kivlehan, the former head of hospitals and speciality brands at Accord, is challenging the termination of her employment in 2024. After a decade with the firm, Kivlehan lost her role—which carried a €90,000 annual salary—in October 2024 on the grounds of redundancy.

The core of Kivlehan’s complaint under the Unfair Dismissals Act 1977 is the timing and communication surrounding the cuts. Kivlehan told the WRC that she was instructed to reassure her Irish staff that their jobs were “safe” shortly before she discovered her own position was on the line.

Beyond the timing, Kivlehan alleges the redundancy was not a neutral business decision. She claims the move followed an “attack” on her professional abilities by the company’s managing director in Ireland, which occurred after she requested a pay rise and was subsequently placed on a coaching plan.

The Strategic Shift: From Biosimilars to Patented Products

Accord Healthcare’s defense rests on a significant change in corporate direction. Padraig O’Brien, the managing director in Ireland, testified that since the company established its presence in 2008, its primary focus had been on generic, off-patent, and “biosimilar” medicines.

However, the company’s leadership decided in 2023 to diversify. Under a novel five-year plan, Accord shifted its strategy toward “pioneering patented products.” This is a critical distinction in pharma; patented products typically offer higher margins and require different clinical and marketing expertise than biosimilars.

O’Brien stated that as part of this pivot, the company decided to merge Kivlehan’s business development role with a vacant marketing post. The goal was to create a single position for a candidate possessing the “sufficient clinical knowledge” required for the new strategic direction.

The Legal Battle: Navigating the WRC

The Workplace Relations Commission (WRC) is now tasked with determining if this restructuring was a genuine redundancy or a pretext for dismissal. In Irish employment law, a genuine redundancy occurs when a role is no longer required, but the process must be fair, transparent, and non-discriminatory.

The tribunal must weigh two competing narratives:

• The Company’s View: A legitimate business evolution required a different skill set, rendering the previous role redundant.
• The Employee’s View: The redundancy was used as a tool to remove a manager who had requested a salary increase and faced friction with senior leadership.

Forward Outlook

This case serves as a cautionary tale for multinational firms operating in Ireland. As companies pivot their portfolios to meet new market demands, the method of restructuring is as important as the strategy itself. If the WRC finds that the redundancy was a cover for a personal or professional dispute, the company could face substantial penalties. Conversely, a ruling in favor of Accord would reinforce the right of companies to restructure roles to align with new commercial goals.